Fig. S2. The numbers of Th17 and Th22 cells in peripheral blood mononuclear cell (PBMC) samples analysed by flow cytometry. As representative samples, PBMC samples from a psoriatic patient (a) before and (b) after one week of betamethasone monotherapy and samples from another psoriatic patient (c) before and (d) after 1 week of calcipotriol/betamethasone combination therapy are shown. CD4+ T cells were selected from PBMC samples (first column). Memory CD4+ T cells were identified as CD4+, CD45RA- T cells (second column). Th17 memory cells were identified from memory CD4+ T cells as CD4+, CD45RA-, CXCR3-, CCR6+ cells (third column). Th22 memory cells were identified from Th17 memory cells as CD4+, CD45RA-, CXCR3-, CCR6+, CCR10+ cells and (fourth column) and skin-homing Th17 cells as CD4+, CD45RA-, CXCR3-, CCR6+, CLA+ cells (fifth column). Both topical therapies reduced the numbers of Th22 cells (fourth column: combination therapy from 10.6% to 7.45% and monotherapy from 9.52% to 4.64%) and skin homing CLA+ Th17 cells (fifth column: combination therapy from 19.5% to 17.2% and monotherapy from 12.6% to 6.91%).